Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
Investor Relations
Latest Financial Results
Q2 2021
Quarterly Results
Ended Jun 30, 2021
Stock Information
Symbol
NYSE American: OGEN
Price
Change
Day Range
52 Wk Range
Company Overview
Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.
Contact Information
Investor Relations
LHA Investor Relations
Kim Golodetz
Senior Vice President, Principal
T: 212-838-3777
kgolodetz@lhai.com
Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000